Irisin levels increase after treatment in patients with newly diagnosed Hashimoto thyroiditis

Purpose Irisin is a newly identified myokine secreted by skeletal muscle and has significant effects on body metabolism. Thyroidal functional state has a profound influence on the metabolism of human body. Therefore, the aim of this study was to investigate the possible changes in serum irisin conce...

Full description

Saved in:
Bibliographic Details
Published inJournal of endocrinological investigation Vol. 42; no. 2; pp. 175 - 181
Main Authors Uc, Z. A., Gorar, S., Mizrak, S., Gullu, S.
Format Journal Article
LanguageEnglish
Published Cham Springer International Publishing 01.02.2019
Springer Nature B.V
Subjects
Online AccessGet full text
ISSN1720-8386
0391-4097
1720-8386
DOI10.1007/s40618-018-0899-8

Cover

Abstract Purpose Irisin is a newly identified myokine secreted by skeletal muscle and has significant effects on body metabolism. Thyroidal functional state has a profound influence on the metabolism of human body. Therefore, the aim of this study was to investigate the possible changes in serum irisin concentrations before and after treatment in hypothyroid subjects. Methods The study included 26 patients with overt hypothyroidism due to Hashimoto thyroiditis and 19 healthy subjects. Baseline serum thyroid function tests and presence of thyroid autoantibodies and levels of creatine kinase (CK) and irisin were measured in both groups. All measurements in the hypothyroid group were repeated after euthyroidism was achieved. Results Serum irisin levels were significantly lower in the hypothyroid groups than the control group ( p  < 0.001). Negative correlation between irisin and thyroid stimulating hormone and CK levels ( r  = − 0.623, p  < 0.001 and r  = − 0.389, p  = 0.008, respectively) and a positive correlation between irisin and free thyroxine (fT4) levels ( r  = 0.570, p  < 0.001) was found. Serum CK levels decreased significantly after treatment ( p  < 0.001). Serum irisin levels significantly increased (from 57.4 to 99.8 U/L, p  < 0.001) when the hypothyroid patients were treated to achieve euthyroidism. Conclusions To the best of our knowledge, this is the first study providing insight that low serum irisin levels significantly increased following treatment to euthyroid state in overt hypothyroid patients with Hashimoto thyroiditis. Larger scale studies are needed to confirm these results and to ensure irisin as a possible biomarker of Hashimoto’s thyroiditis.
AbstractList Irisin is a newly identified myokine secreted by skeletal muscle and has significant effects on body metabolism. Thyroidal functional state has a profound influence on the metabolism of human body. Therefore, the aim of this study was to investigate the possible changes in serum irisin concentrations before and after treatment in hypothyroid subjects. The study included 26 patients with overt hypothyroidism due to Hashimoto thyroiditis and 19 healthy subjects. Baseline serum thyroid function tests and presence of thyroid autoantibodies and levels of creatine kinase (CK) and irisin were measured in both groups. All measurements in the hypothyroid group were repeated after euthyroidism was achieved. Serum irisin levels were significantly lower in the hypothyroid groups than the control group (p < 0.001). Negative correlation between irisin and thyroid stimulating hormone and CK levels (r = - 0.623, p < 0.001 and r = - 0.389, p = 0.008, respectively) and a positive correlation between irisin and free thyroxine (fT4) levels (r = 0.570, p < 0.001) was found. Serum CK levels decreased significantly after treatment (p < 0.001). Serum irisin levels significantly increased (from 57.4 to 99.8 U/L, p < 0.001) when the hypothyroid patients were treated to achieve euthyroidism. To the best of our knowledge, this is the first study providing insight that low serum irisin levels significantly increased following treatment to euthyroid state in overt hypothyroid patients with Hashimoto thyroiditis. Larger scale studies are needed to confirm these results and to ensure irisin as a possible biomarker of Hashimoto's thyroiditis.
PurposeIrisin is a newly identified myokine secreted by skeletal muscle and has significant effects on body metabolism. Thyroidal functional state has a profound influence on the metabolism of human body. Therefore, the aim of this study was to investigate the possible changes in serum irisin concentrations before and after treatment in hypothyroid subjects.MethodsThe study included 26 patients with overt hypothyroidism due to Hashimoto thyroiditis and 19 healthy subjects. Baseline serum thyroid function tests and presence of thyroid autoantibodies and levels of creatine kinase (CK) and irisin were measured in both groups. All measurements in the hypothyroid group were repeated after euthyroidism was achieved.ResultsSerum irisin levels were significantly lower in the hypothyroid groups than the control group (p < 0.001). Negative correlation between irisin and thyroid stimulating hormone and CK levels (r = − 0.623, p < 0.001 and r = − 0.389, p = 0.008, respectively) and a positive correlation between irisin and free thyroxine (fT4) levels (r = 0.570, p < 0.001) was found. Serum CK levels decreased significantly after treatment (p < 0.001). Serum irisin levels significantly increased (from 57.4 to 99.8 U/L, p < 0.001) when the hypothyroid patients were treated to achieve euthyroidism.ConclusionsTo the best of our knowledge, this is the first study providing insight that low serum irisin levels significantly increased following treatment to euthyroid state in overt hypothyroid patients with Hashimoto thyroiditis. Larger scale studies are needed to confirm these results and to ensure irisin as a possible biomarker of Hashimoto’s thyroiditis.
Purpose Irisin is a newly identified myokine secreted by skeletal muscle and has significant effects on body metabolism. Thyroidal functional state has a profound influence on the metabolism of human body. Therefore, the aim of this study was to investigate the possible changes in serum irisin concentrations before and after treatment in hypothyroid subjects. Methods The study included 26 patients with overt hypothyroidism due to Hashimoto thyroiditis and 19 healthy subjects. Baseline serum thyroid function tests and presence of thyroid autoantibodies and levels of creatine kinase (CK) and irisin were measured in both groups. All measurements in the hypothyroid group were repeated after euthyroidism was achieved. Results Serum irisin levels were significantly lower in the hypothyroid groups than the control group ( p  < 0.001). Negative correlation between irisin and thyroid stimulating hormone and CK levels ( r  = − 0.623, p  < 0.001 and r  = − 0.389, p  = 0.008, respectively) and a positive correlation between irisin and free thyroxine (fT4) levels ( r  = 0.570, p  < 0.001) was found. Serum CK levels decreased significantly after treatment ( p  < 0.001). Serum irisin levels significantly increased (from 57.4 to 99.8 U/L, p  < 0.001) when the hypothyroid patients were treated to achieve euthyroidism. Conclusions To the best of our knowledge, this is the first study providing insight that low serum irisin levels significantly increased following treatment to euthyroid state in overt hypothyroid patients with Hashimoto thyroiditis. Larger scale studies are needed to confirm these results and to ensure irisin as a possible biomarker of Hashimoto’s thyroiditis.
Irisin is a newly identified myokine secreted by skeletal muscle and has significant effects on body metabolism. Thyroidal functional state has a profound influence on the metabolism of human body. Therefore, the aim of this study was to investigate the possible changes in serum irisin concentrations before and after treatment in hypothyroid subjects.PURPOSEIrisin is a newly identified myokine secreted by skeletal muscle and has significant effects on body metabolism. Thyroidal functional state has a profound influence on the metabolism of human body. Therefore, the aim of this study was to investigate the possible changes in serum irisin concentrations before and after treatment in hypothyroid subjects.The study included 26 patients with overt hypothyroidism due to Hashimoto thyroiditis and 19 healthy subjects. Baseline serum thyroid function tests and presence of thyroid autoantibodies and levels of creatine kinase (CK) and irisin were measured in both groups. All measurements in the hypothyroid group were repeated after euthyroidism was achieved.METHODSThe study included 26 patients with overt hypothyroidism due to Hashimoto thyroiditis and 19 healthy subjects. Baseline serum thyroid function tests and presence of thyroid autoantibodies and levels of creatine kinase (CK) and irisin were measured in both groups. All measurements in the hypothyroid group were repeated after euthyroidism was achieved.Serum irisin levels were significantly lower in the hypothyroid groups than the control group (p < 0.001). Negative correlation between irisin and thyroid stimulating hormone and CK levels (r = - 0.623, p < 0.001 and r = - 0.389, p = 0.008, respectively) and a positive correlation between irisin and free thyroxine (fT4) levels (r = 0.570, p < 0.001) was found. Serum CK levels decreased significantly after treatment (p < 0.001). Serum irisin levels significantly increased (from 57.4 to 99.8 U/L, p < 0.001) when the hypothyroid patients were treated to achieve euthyroidism.RESULTSSerum irisin levels were significantly lower in the hypothyroid groups than the control group (p < 0.001). Negative correlation between irisin and thyroid stimulating hormone and CK levels (r = - 0.623, p < 0.001 and r = - 0.389, p = 0.008, respectively) and a positive correlation between irisin and free thyroxine (fT4) levels (r = 0.570, p < 0.001) was found. Serum CK levels decreased significantly after treatment (p < 0.001). Serum irisin levels significantly increased (from 57.4 to 99.8 U/L, p < 0.001) when the hypothyroid patients were treated to achieve euthyroidism.To the best of our knowledge, this is the first study providing insight that low serum irisin levels significantly increased following treatment to euthyroid state in overt hypothyroid patients with Hashimoto thyroiditis. Larger scale studies are needed to confirm these results and to ensure irisin as a possible biomarker of Hashimoto's thyroiditis.CONCLUSIONSTo the best of our knowledge, this is the first study providing insight that low serum irisin levels significantly increased following treatment to euthyroid state in overt hypothyroid patients with Hashimoto thyroiditis. Larger scale studies are needed to confirm these results and to ensure irisin as a possible biomarker of Hashimoto's thyroiditis.
Author Mizrak, S.
Uc, Z. A.
Gullu, S.
Gorar, S.
Author_xml – sequence: 1
  givenname: Z. A.
  surname: Uc
  fullname: Uc, Z. A.
  email: ziynetalp@yahoo.com
  organization: Department of Endocrinology, Usak University School of Medicine
– sequence: 2
  givenname: S.
  surname: Gorar
  fullname: Gorar, S.
  organization: Department of Endocrinology, Antalya Training and Research Hospital
– sequence: 3
  givenname: S.
  surname: Mizrak
  fullname: Mizrak, S.
  organization: Department of Biochemistry, Usak University School of Medicine
– sequence: 4
  givenname: S.
  surname: Gullu
  fullname: Gullu, S.
  organization: Department of Endocrinology, Ankara University School of Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29777516$$D View this record in MEDLINE/PubMed
BookMark eNp9kU1rGzEQhkVJaT7aH9BLEPTSy6Yaaa2PYwltEgj00h6LkLWzscKu5Ehyjf99ZZzQEEgPg95BzzsM856So5giEvIR2AUwpr6UnknQHduXNqbTb8gJKM46LbQ8eqaPyWkp94wJJbR6R465UUotQJ6Q3zc5lBDphH9wKjREn9EVpG6smGltTZ0x1vZB166GJgvdhrqiEbfTjg7B3cVUcKDXrqzCnGqidbXLKQyhhvKevB3dVPDD43tGfn3_9vPyurv9cXVz-fW280Lx2o2LXsmeLdxSoVROCsm9Uchx5IhsRHTGoZLgvJGGGc-BQ98ULAfNwffijHw-zF3n9LDBUu0cisdpchHTpljOepACQKmGfnqB3qdNjm07y0EDcCGFadT5I7VZzjjYdQ6zyzv7dLgGqAPgcyol42h9qO1AKdbswmSB2X1E9hCRZftqEVndnPDC-TT8fx5-8JTGxjvM_5Z-3fQXX9WjGw
CitedBy_id crossref_primary_10_12998_wjcc_v10_i4_1190
crossref_primary_10_1155_2021_3116068
crossref_primary_10_1007_s40618_020_01432_0
crossref_primary_10_1155_2019_3814687
crossref_primary_10_1007_s40619_022_01177_3
crossref_primary_10_1210_clinem_dgac575
crossref_primary_10_1016_j_biochi_2021_06_016
crossref_primary_10_1177_03000605211018422
crossref_primary_10_1177_2042018820917869
crossref_primary_10_1155_2020_2182735
Cites_doi 10.1210/jc.2013-2312
10.1007/s40618-017-0690-2
10.1016/j.metabol.2012.09.002
10.1016/j.metabol.2015.01.001
10.1007/s40618-017-0661-7
10.1089/thy.1995.5.481
10.1016/j.peptides.2014.03.021
10.1089/thy.2016.0098
10.3109/07853890.2015.1085126
10.1016/j.metabol.2013.10.005
10.1016/j.peptides.2014.07.021
10.1111/cen.13527
10.3758/BF03193146
10.1590/2359-3997000000077
10.1016/j.peptides.2012.11.014
10.1371/journal.pone.0072858
10.1038/nrendo.2013.238
10.5603/EP.a2016.0030
10.1007/s00421-014-2922-x
10.1016/j.metabol.2013.02.002
10.1089/thy.2007.0256
10.1210/jc.2009-0782
10.1038/nature10777
10.1371/journal.pone.0060563
10.1155/2012/960363
ContentType Journal Article
Copyright Italian Society of Endocrinology (SIE) 2018
Copyright Springer Nature B.V. 2019
Copyright_xml – notice: Italian Society of Endocrinology (SIE) 2018
– notice: Copyright Springer Nature B.V. 2019
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
K9.
NAPCQ
7X8
DOI 10.1007/s40618-018-0899-8
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitleList MEDLINE
ProQuest Health & Medical Complete (Alumni)

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1720-8386
EndPage 181
ExternalDocumentID 29777516
10_1007_s40618_018_0899_8
Genre Journal Article
GroupedDBID ---
-EM
0R~
203
4.4
406
5GY
5RE
8YF
96X
AACDK
AAHNG
AAJBT
AAJKR
AANZL
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAZMS
ABAKF
ABDZT
ABECU
ABFTV
ABHLI
ABIPD
ABJNI
ABJOX
ABKCH
ABMQK
ABPLI
ABQBU
ABTEG
ABTKH
ABTMW
ABXPI
ACAOD
ACDTI
ACGFS
ACHSB
ACKNC
ACMLO
ACOKC
ACPIV
ACPRK
ACZOJ
ADHHG
ADINQ
ADJJI
ADKNI
ADKPE
ADURQ
ADYFF
ADZKW
AEFQL
AEGNC
AEJHL
AEJRE
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETCA
AEVLU
AEXYK
AFBBN
AFQWF
AFZKB
AGAYW
AGDGC
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AIAKS
AIGIU
AILAN
AITGF
AJRNO
AJZVZ
AKLTO
AKMHD
ALFXC
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMXSW
AMYLF
AMYQR
ANMIH
ASPBG
AUKKA
AVWKF
AXYYD
BGNMA
CSCUP
DNIVK
DPUIP
EBLON
EBS
EIOEI
EJD
ESBYG
F5P
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FYJPI
GGCAI
GGRSB
GJIRD
GQ7
HG6
HRMNR
I0C
IKXTQ
IMOTQ
ITM
IWAJR
J-C
JBSCW
JZLTJ
KOV
LLZTM
M4Y
NPVJJ
NQJWS
NU0
O93
O9G
O9J
P2P
PT4
RLLFE
ROL
RSV
SHX
SISQX
SJYHP
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
TSG
U9L
UG4
UOJIU
UTJUX
UZXMN
VFIZW
W48
Z7U
Z83
Z87
ZMTXR
ZOVNA
.GJ
53G
8RF
AAEWM
AAIAL
AANXM
AAYTO
AAYXX
ABBRH
ABDBE
ABFSG
ACSTC
ACUDM
AEBTG
AEKMD
AEODN
AEZWR
AFDZB
AFHIU
AFOHR
AHPBZ
AHSBF
AHWEU
AI.
AIXLP
AJBLW
ATHPR
AYFIA
AZFZN
CITATION
GRRUI
RHV
SCLPG
SDE
VH1
ZGI
ZXP
CGR
CUY
CVF
ECM
EIF
NPM
ABRTQ
K9.
NAPCQ
7X8
ID FETCH-LOGICAL-c372t-f5476405ab7e67a6362c97e2ef2ee0feea9ae761ac96909c212146901bd821c43
IEDL.DBID AGYKE
ISSN 1720-8386
0391-4097
IngestDate Thu Sep 04 19:48:33 EDT 2025
Wed Sep 17 13:51:20 EDT 2025
Thu Apr 03 07:05:01 EDT 2025
Thu Apr 24 23:10:42 EDT 2025
Tue Jul 01 02:10:46 EDT 2025
Fri Feb 21 02:32:48 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Overt hypothyroidism
Irisin
Hypothyroidism
Hashimoto thyroiditis
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c372t-f5476405ab7e67a6362c97e2ef2ee0feea9ae761ac96909c212146901bd821c43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 29777516
PQID 2181123639
PQPubID 2043718
PageCount 7
ParticipantIDs proquest_miscellaneous_2041631177
proquest_journals_2181123639
pubmed_primary_29777516
crossref_citationtrail_10_1007_s40618_018_0899_8
crossref_primary_10_1007_s40618_018_0899_8
springer_journals_10_1007_s40618_018_0899_8
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-02-01
PublicationDateYYYYMMDD 2019-02-01
PublicationDate_xml – month: 02
  year: 2019
  text: 2019-02-01
  day: 01
PublicationDecade 2010
PublicationPlace Cham
PublicationPlace_xml – name: Cham
– name: Italy
– name: Heidelberg
PublicationSubtitle Official Journal of Italian Society of Endocrinology (SIE)
PublicationTitle Journal of endocrinological investigation
PublicationTitleAbbrev J Endocrinol Invest
PublicationTitleAlternate J Endocrinol Invest
PublicationYear 2019
Publisher Springer International Publishing
Springer Nature B.V
Publisher_xml – name: Springer International Publishing
– name: Springer Nature B.V
References Panagiotou, Pazaitou-Panayiotou, Paschou, Komninou, Kalogeris, Vryonidou, Mantzoros (CR14) 2016; 26
Roberts, Bayless, Company, Jenkins, Padilla, Childs, Martin, Dalbo, Booth, Rector, Laughlin (CR19) 2013; 62
Faul, Erdfelder, Lang, Buchner (CR17) 2007; 39
Ellefsen, Vikmoen, Slettaløkken, Whist, Nygaard, Hollan, Rauk, Vegge, Strand, Raastad, Rønnestad (CR22) 2014; 114
Aydin (CR7) 2014; 56
Ates, Altay, Topcuoglu, Yilmaz (CR12) 2016; 60
Gouni-Berthold, Berthold, Huh, Berman, Spenrath, Krone, Mantzoros (CR21) 2013
Gallo, Piantanida, Veronesi, Lai, Sassi, Lombardi, Masiello, Premoli, Bianconi, Cusini, Rosetti, Tanda, Toniolo, Ferrario, Bartalena (CR25) 2017; 40
Moon, Mantzoros (CR5) 2014; 63
Silva (CR1) 1995; 5
Lapa, Maya, Wagner, Arias-Loza, Werner, Herrmann, Higuchi (CR9) 2015; 47
Roca-Rivada, Castelao, Senin, Landrove, Baltar, Belen Crujeiras, Seoane, Casanueva, Pardo (CR6) 2013; 8
Zybek-Kocik, Sawicka-Gutaj, Wrotkowska, Sowinski, Ruchala (CR15) 2016; 67
Salvatore, Simonides, Dentice, Zavacki, Larsen (CR11) 2014; 10
Visser, Heemstra, Swagemakers, Ozgur, Corssmit, Burggraaf, van Ijcken, van der Spek, Smit, Visser (CR10) 2009; 94
Stengel, Hofmann, Goebel-Stengel, Elbelt, Kobelt, Klapp (CR20) 2013; 39
Samy, Ismail, Nassra (CR23) 2015; 64
Bostrom, Wu, Jedrychowski, Korde, Ye, Lo, Rasbach, Bostrom, Choi, Long, Kajimura, Zingaretti, Vind, Tu, Cinti, Hojlund, Gygi, Spiegelman (CR3) 2012; 481
Lahesmaa, Orava, Schalin-Jantti, Soinio, Hannukainen, Noponen, Kirjavainen, Iida, Kudomi, Enerback, Virtanen, Nuutila (CR8) 2014; 99
Huh, Panagiotou, Mougios, Brinkoetter, Vamvini, Schneider, Mantzoros (CR4) 2012; 61
Sforza, Rosenfarb, Rujelman, RosmarinM, Frigerio, Fossati, Caruso, Faingold, Meroño, Brenta (CR18) 2017; 40
Simonides, van Hardeveld (CR2) 2008; 18
Zybek-Kocik, Sawicka-Gutaj, Szczepanek-Parulska, Andrusiewicz, Waligórska-Stachura, Białas, Krauze, Guzik, Skrobisz, Ruchała (CR16) 2017
Baird, Graham, Baker, Bickerstaff (CR24) 2012
Ruchala, Zybek, Szczepanek-Parulska (CR13) 2014; 60
WE Visser (899_CR10) 2009; 94
MD Roberts (899_CR19) 2013; 62
MF Baird (899_CR24) 2012
N Sforza (899_CR18) 2017; 40
I Gouni-Berthold (899_CR21) 2013
C Lapa (899_CR9) 2015; 47
D Gallo (899_CR25) 2017; 40
M Lahesmaa (899_CR8) 2014; 99
F Faul (899_CR17) 2007; 39
JE Silva (899_CR1) 1995; 5
JY Huh (899_CR4) 2012; 61
A Zybek-Kocik (899_CR16) 2017
A Stengel (899_CR20) 2013; 39
D Salvatore (899_CR11) 2014; 10
M Ruchala (899_CR13) 2014; 60
DM Samy (899_CR23) 2015; 64
P Bostrom (899_CR3) 2012; 481
A Roca-Rivada (899_CR6) 2013; 8
G Panagiotou (899_CR14) 2016; 26
HS Moon (899_CR5) 2014; 63
WS Simonides (899_CR2) 2008; 18
S Aydin (899_CR7) 2014; 56
A Zybek-Kocik (899_CR15) 2016; 67
S Ellefsen (899_CR22) 2014; 114
I Ates (899_CR12) 2016; 60
References_xml – volume: 99
  start-page: E28
  year: 2014
  end-page: E35
  ident: CR8
  article-title: Hyperthyroidism increases brown fat metabolism in humans
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2013-2312
– volume: 40
  start-page: 1303
  year: 2017
  end-page: 1310
  ident: CR18
  article-title: Hypothyroidism in hospitalized elderly patients: a sign of worse prognosis
  publication-title: J Endocrinol Invest
  doi: 10.1007/s40618-017-0690-2
– volume: 61
  start-page: 1725
  year: 2012
  end-page: 1738
  ident: CR4
  article-title: FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise
  publication-title: Metab Clin Exp
  doi: 10.1016/j.metabol.2012.09.002
– volume: 64
  start-page: 804
  issue: 7
  year: 2015
  end-page: 813
  ident: CR23
  article-title: Circulating irisin concentrations in rat models of thyroid dysfunction—effect of exercise
  publication-title: Metabolism
  doi: 10.1016/j.metabol.2015.01.001
– volume: 40
  start-page: 1099
  year: 2017
  end-page: 1106
  ident: CR25
  article-title: Physical performance in newly diagnosed hypothyroidism: a pilot study
  publication-title: J Endocrinol Invest
  doi: 10.1007/s40618-017-0661-7
– volume: 5
  start-page: 481
  year: 1995
  end-page: 492
  ident: CR1
  article-title: Thyroid hormone control of thermogenesis and energy balance
  publication-title: Thyroid
  doi: 10.1089/thy.1995.5.481
– volume: 56
  start-page: 94
  year: 2014
  end-page: 110
  ident: CR7
  article-title: Three new players in energy regulation: preptin, adropin and irisin
  publication-title: Peptides
  doi: 10.1016/j.peptides.2014.03.021
– volume: 26
  start-page: 1039
  issue: 8
  year: 2016
  end-page: 1045
  ident: CR14
  article-title: Changes of thyroid hormone levels within the normal and/or subclinical hyper- or hypothyroid range do not affect circulating irisin levels in humans
  publication-title: Thyroid
  doi: 10.1089/thy.2016.0098
– volume: 47
  start-page: 538
  year: 2015
  end-page: 545
  ident: CR9
  article-title: Activation of brown adipose tissue in hypothyroidism
  publication-title: Ann Med
  doi: 10.3109/07853890.2015.1085126
– volume: 63
  start-page: 188
  year: 2014
  end-page: 193
  ident: CR5
  article-title: Regulation of cell proliferation and malignant potential by irisin in endometrial, colon, thyroid and esophageal cancer cell lines
  publication-title: Metab Clin Exp
  doi: 10.1016/j.metabol.2013.10.005
– volume: 60
  start-page: 51
  year: 2014
  end-page: 55
  ident: CR13
  article-title: Serum irisin levels and thyroid function-newly discovered association
  publication-title: Peptides
  doi: 10.1016/j.peptides.2014.07.021
– year: 2017
  ident: CR16
  article-title: The association between irisin and muscle metabolism in different thyroid disorders
  publication-title: Clin Endocrinol
  doi: 10.1111/cen.13527
– volume: 39
  start-page: 175
  issue: 2
  year: 2007
  end-page: 191
  ident: CR17
  article-title: G*Power 3: a flexible statistical power analysis program for the social, behavioural, and biomedical sciences
  publication-title: Behav Res Methods
  doi: 10.3758/BF03193146
– volume: 60
  start-page: 95
  year: 2016
  end-page: 100
  ident: CR12
  article-title: Circulating levels of irisin is elevated in hypothyroidism, a case-control study
  publication-title: Arch Endocrinol Metab
  doi: 10.1590/2359-3997000000077
– volume: 39
  start-page: 125
  year: 2013
  end-page: 130
  ident: CR20
  article-title: Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity—correlation with body mass index
  publication-title: Peptides
  doi: 10.1016/j.peptides.2012.11.014
– year: 2013
  ident: CR21
  article-title: Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells ex vivo
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0072858
– volume: 10
  start-page: 206
  year: 2014
  end-page: 214
  ident: CR11
  article-title: Thyroid hormones and skeletal muscle—new insights and potential implications
  publication-title: Nat Rev Endocrinol
  doi: 10.1038/nrendo.2013.238
– volume: 67
  start-page: 476
  issue: 5
  year: 2016
  end-page: 480
  ident: CR15
  article-title: Time-dependent irisin concentration changes in patients affected by overt hypothyroidism
  publication-title: Endokrynol Pol
  doi: 10.5603/EP.a2016.0030
– volume: 114
  start-page: 1875
  issue: 9
  year: 2014
  end-page: 1888
  ident: CR22
  article-title: Irisin and FNDC5: effects of 12-week strength training, and relations to muscle phenotype and body mass composition in untrained women
  publication-title: Eur J Appl Physiol
  doi: 10.1007/s00421-014-2922-x
– volume: 62
  start-page: 1052
  year: 2013
  end-page: 1056
  ident: CR19
  article-title: Elevated skeletal muscle irisin precursor FNDC5 mRNA in obese OLETF rats
  publication-title: Metabolism
  doi: 10.1016/j.metabol.2013.02.002
– volume: 18
  start-page: 205e216
  year: 2008
  ident: CR2
  article-title: Thyroid hormone as a determinant of metabolic and contractile phenotype of skeletal muscle
  publication-title: Thyroid
  doi: 10.1089/thy.2007.0256
– volume: 94
  start-page: 3487
  year: 2009
  end-page: 3496
  ident: CR10
  article-title: Physiological thyroid hormone levels regulate numerous skeletal muscle transcripts
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2009-0782
– volume: 481
  start-page: 463
  year: 2012
  end-page: 468
  ident: CR3
  article-title: A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis
  publication-title: Nature
  doi: 10.1038/nature10777
– volume: 8
  start-page: e60563
  year: 2013
  ident: CR6
  article-title: FNDC5/irisin is not only a myokine but also an adipokine
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0060563
– year: 2012
  ident: CR24
  article-title: Creatine-kinase- and exercise-related muscle damage implications for muscle performance and recovery
  publication-title: J Nutr Metab
  doi: 10.1155/2012/960363
– volume: 47
  start-page: 538
  year: 2015
  ident: 899_CR9
  publication-title: Ann Med
  doi: 10.3109/07853890.2015.1085126
– volume: 63
  start-page: 188
  year: 2014
  ident: 899_CR5
  publication-title: Metab Clin Exp
  doi: 10.1016/j.metabol.2013.10.005
– volume: 60
  start-page: 51
  year: 2014
  ident: 899_CR13
  publication-title: Peptides
  doi: 10.1016/j.peptides.2014.07.021
– volume: 39
  start-page: 125
  year: 2013
  ident: 899_CR20
  publication-title: Peptides
  doi: 10.1016/j.peptides.2012.11.014
– volume: 26
  start-page: 1039
  issue: 8
  year: 2016
  ident: 899_CR14
  publication-title: Thyroid
  doi: 10.1089/thy.2016.0098
– volume: 114
  start-page: 1875
  issue: 9
  year: 2014
  ident: 899_CR22
  publication-title: Eur J Appl Physiol
  doi: 10.1007/s00421-014-2922-x
– volume: 61
  start-page: 1725
  year: 2012
  ident: 899_CR4
  publication-title: Metab Clin Exp
  doi: 10.1016/j.metabol.2012.09.002
– volume: 481
  start-page: 463
  year: 2012
  ident: 899_CR3
  publication-title: Nature
  doi: 10.1038/nature10777
– volume: 8
  start-page: e60563
  year: 2013
  ident: 899_CR6
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0060563
– volume: 39
  start-page: 175
  issue: 2
  year: 2007
  ident: 899_CR17
  publication-title: Behav Res Methods
  doi: 10.3758/BF03193146
– volume: 62
  start-page: 1052
  year: 2013
  ident: 899_CR19
  publication-title: Metabolism
  doi: 10.1016/j.metabol.2013.02.002
– volume: 99
  start-page: E28
  year: 2014
  ident: 899_CR8
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2013-2312
– volume: 40
  start-page: 1303
  year: 2017
  ident: 899_CR18
  publication-title: J Endocrinol Invest
  doi: 10.1007/s40618-017-0690-2
– year: 2012
  ident: 899_CR24
  publication-title: J Nutr Metab
  doi: 10.1155/2012/960363
– volume: 94
  start-page: 3487
  year: 2009
  ident: 899_CR10
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2009-0782
– volume: 67
  start-page: 476
  issue: 5
  year: 2016
  ident: 899_CR15
  publication-title: Endokrynol Pol
  doi: 10.5603/EP.a2016.0030
– volume: 40
  start-page: 1099
  year: 2017
  ident: 899_CR25
  publication-title: J Endocrinol Invest
  doi: 10.1007/s40618-017-0661-7
– volume: 5
  start-page: 481
  year: 1995
  ident: 899_CR1
  publication-title: Thyroid
  doi: 10.1089/thy.1995.5.481
– year: 2017
  ident: 899_CR16
  publication-title: Clin Endocrinol
  doi: 10.1111/cen.13527
– year: 2013
  ident: 899_CR21
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0072858
– volume: 18
  start-page: 205e216
  year: 2008
  ident: 899_CR2
  publication-title: Thyroid
  doi: 10.1089/thy.2007.0256
– volume: 10
  start-page: 206
  year: 2014
  ident: 899_CR11
  publication-title: Nat Rev Endocrinol
  doi: 10.1038/nrendo.2013.238
– volume: 64
  start-page: 804
  issue: 7
  year: 2015
  ident: 899_CR23
  publication-title: Metabolism
  doi: 10.1016/j.metabol.2015.01.001
– volume: 56
  start-page: 94
  year: 2014
  ident: 899_CR7
  publication-title: Peptides
  doi: 10.1016/j.peptides.2014.03.021
– volume: 60
  start-page: 95
  year: 2016
  ident: 899_CR12
  publication-title: Arch Endocrinol Metab
  doi: 10.1590/2359-3997000000077
SSID ssj0037387
Score 2.2745614
Snippet Purpose Irisin is a newly identified myokine secreted by skeletal muscle and has significant effects on body metabolism. Thyroidal functional state has a...
Irisin is a newly identified myokine secreted by skeletal muscle and has significant effects on body metabolism. Thyroidal functional state has a profound...
PurposeIrisin is a newly identified myokine secreted by skeletal muscle and has significant effects on body metabolism. Thyroidal functional state has a...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 175
SubjectTerms Adult
Autoantibodies
Creatine
Creatine kinase
Creatine Kinase - blood
Endocrinology
Female
Fibronectins - blood
Hashimoto Disease - blood
Hashimoto Disease - drug therapy
Hormone Replacement Therapy
Humans
Hypothyroidism
Male
Medicine
Medicine & Public Health
Metabolic Diseases
Metabolism
Original Article
Patients
Skeletal muscle
Thyroid
Thyroid Function Tests
Thyroid gland
Thyroiditis
Thyrotropin - blood
Thyroxine
Thyroxine - blood
Thyroxine - therapeutic use
Treatment Outcome
Title Irisin levels increase after treatment in patients with newly diagnosed Hashimoto thyroiditis
URI https://link.springer.com/article/10.1007/s40618-018-0899-8
https://www.ncbi.nlm.nih.gov/pubmed/29777516
https://www.proquest.com/docview/2181123639
https://www.proquest.com/docview/2041631177
Volume 42
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVLSH
  databaseName: SpringerLink Journals
  customDbUrl:
  mediaType: online
  eissn: 1720-8386
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0037387
  issn: 1720-8386
  databaseCode: AFBBN
  dateStart: 19970101
  isFulltext: true
  providerName: Library Specific Holdings
– providerCode: PRVAVX
  databaseName: SpringerLINK - Czech Republic Consortium
  customDbUrl:
  eissn: 1720-8386
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0037387
  issn: 1720-8386
  databaseCode: AGYKE
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: http://link.springer.com
  providerName: Springer Nature
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dS8MwED90A_HF74_qHBF8Uir9WtM8TtkcyvbkYD5IabIUhqOTdXvQv967folOBaF9StKmySX3u97ldwAXRDkVoeFhuiTBnnI8U0hHZVGECLfxypiY-gO_N_TuR61RcY47LaPdS5dktlNXh91I9VDgFTEqC2EG61BvkX1Sg3r77umhU27AxNXDSwfmTw2_qqAVXLniE81UTXcbHstO5hEmL9fLhbxW79_4G__5FTuwVUBP1s5lZRfWdLIHG_3Cub4Pz5RtfpKwKcURpWySEKBMNcvSiLMqIh0LWMHGmjL6jcsQmU_f2DgP2tNj1qMETSgCM4ZSMJ9NxsSbdADDbufxtmcW2RdM5XJnYcYtj_sI5yLJtc8jHzWdElw7Ona0tmKtideb-3akBFrYQqEOtMnWtuU4cGzluYdQS2aJPgYmsL5PLDCWCjwd29LyYzfwlNRaSotHBljlhISqoCanDBnTsCJVzoYttOjGYQsDAy6rJq85L8dflRvlLIfFEk1DwjZEPeMKA86rYlxc5DGJEj1bYh2L8Cr5tQ04yqWjepuDyJm3bN-Aq3KmPx_-a1dO_lX7FDYRoIk8SrwBtcV8qc8QBC1kE4W-e3MzaBbC_wGgsP63
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3JTsMwEB1BKwEX9iWsRuIESpXFjeNjhYCylFOR4ICi2HWkiipFpD3A1zOTDbFKSMnJ48Sxx57nzPgNwBFRTsW48bB90mCuPW5L5ek8ihDhNl45E1PvNuje8av79n15jjurot0rl2S-UteH3cj0UOAVMSpLaYez0ORuGPIGNDsXD9dn1QJMXD2icmD-VPGzCfqGK7_5RHNTc74E_aqRRYTJU2s6US399oW_8Z9fsQyLJfRknUJXVmDGpKsw1yud62vwSNnmhykbURxRxoYpAcrMsDyNOKsj0rGAlWysGaPfuAyR-eiVDYqgPTNgXUrQhCowZqgFL-PhgHiT1uHu_Kx_2rXL7Au29oU3sZM2FwHCuVgJE4g4QEunpTCeSTxjnMQY4vUWgRtriTtsqdEGurTXdtUg9FzN_Q1opOPUbAGTKB8QC4yjQ24SVzlB4odcK2OUckRsgVMNSKRLanLKkDGKalLlvNsih27stii04Liu8lzwcvwlvFuNclRO0SwibEPUM7604LAuxslFHpM4NeMpyjiEV8mvbcFmoR312zxEzqLtBhacVCP98fBfm7L9L-kDmO_2ezfRzeXt9Q4sIFiTRcT4LjQmL1Ozh4BoovbLCfAOxnkAOw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8QwFH7oCOLFfalrBE9Ktds0zVHUcVzxoKAHqU2awuDQEds56K_3vW7iCiK0pyZtmrz0fen78j2ALZKcinDhYbpkwZ5yPFNIRxUsQoTbeBRKTBeXfvfGO71t31Z5TrOa7V6HJMs9DaTSlOZ7T3Gy12x8IzdEJCxSVxbCDEZhzEPn1m7B2P7x3dlR_TEm3R5eBzO_q_jRHX3BmF_io4Xb6UzBQ93gkm3yuDvM5a56_aTl-I83mobJCpKy_dKGZmBEp7MwflEF3efgnrLQ91LWJ35RxnopAc1MsyK9OGuY6niBVSqtGaPfuwwRe_-FxSWZT8esS4mb0DQGDK3jedCLSU9pHm46R9cHXbPKymAqlzu5mbQ97iPMiyTXPo989IBKcO3oxNHaSrQmvW_u25ESuPIWCn2jTWtwW8aBYyvPXYBWOkj1EjCB5X1Sh7FU4OnElpafuIGnpNZSWjwywKoHJ1SVZDllzuiHjdhy0W2hRSd2WxgYsN1UeSr1On4rvFqPeFhN3SwkzEOSNK4wYLO5jJOOIilRqgdDLGMRjqV4twGLpaU0T3MQUfO27RuwU4_6-81_bMryn0pvwPjVYSc8P7k8W4EJxHCiJJKvQit_Huo1xEm5XK_mwhsvRwkW
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Irisin+levels+increase+after+treatment+in+patients+with+newly+diagnosed+Hashimoto+thyroiditis&rft.jtitle=Journal+of+endocrinological+investigation&rft.au=Uc%2C+Z+A&rft.au=Gorar%2C+S&rft.au=Mizrak%2C+S&rft.au=Gullu%2C+S&rft.date=2019-02-01&rft.issn=1720-8386&rft.eissn=1720-8386&rft.volume=42&rft.issue=2&rft.spage=175&rft_id=info:doi/10.1007%2Fs40618-018-0899-8&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1720-8386&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1720-8386&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1720-8386&client=summon